中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南-《介入放射学杂志》

参考文献/References:

［1］ Wang FS， Fan JG， Zhang Z， et al. The global burden of liver disease： the major impact of China［J］. Hepatology， 2014， 60：2099- 2108.
［2］ Park JW， Chen M， Colombo M， et al. Global patterns of hepatocellular carcinoma management from diagnosis to death： the BRIDGE Study［J］. Liver Int， 2015， 35： 2155- 2166.
［3］ Shi M， Lu LG， Fang WQ， et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma： single- blind， randomized trial［J］. J Natl Cancer Inst， 2013， 105： 59- 68.
［4］中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范（2017年版）［J］. 中华消化外科杂志， 2017， 16： 635- 647.
［5］中华人民共和国卫生部．原发性肝癌诊疗规范（2011年版）［J］．临床肝胆病杂志， 2011， 27： 1141- 1159．
［6］ Basile A， Carrafiello G， Ierardi AM， et al. Quality- improvement guidelines for hepatic transarterial chemoembolization［J］. Cardiovasc Intervent Radiol， 2012， 35： 765- 774.
［7］ Gaba RC， Lokken RP， Hickey RM， et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy［J］. J Vasc Interv Radiol， 2017， 28： 1210.e3- 1223.e3.
［8］中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南（2015年版）［J］．中国肝脏病杂志·电子版，2015，7： 1- 18．
［9］ Jang JW， Choi JY， Bae SH， et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo- lipiodolization［J］. Hepatology， 2006， 43： 233- 240.
［10］ Oken MM， Creech RH， Tormey DC， et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group［J］. Am J Clin Oncol， 1982， 5： 649- 655.
［11］中华医学会肝病学分会肝癌学组． HBV/HCV相关性肝细胞癌抗病毒治疗专家建议［J］．实用肝脏病杂志， 2013， 16： 188- 192．
［12］中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南（2010年版）［J］．临床肝胆病杂志， 2011， 27： 1- 16．
［13］ Lewandowski RJ， Sato KT， Atassi B， et al. Radioembolization with 90Y microspheres： angiographic and technical considerations［J］. Cardiovasc Intervent Radiol， 2007， 30： 571- 592.
［14］ Kim HC， Chung JW， Lee W， et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization［J］. Radiographics， 2005， 25： S25- S39.
［15］ Woo S， Kim HC， Chung JW， et al. Chemoembolization of extrahepatic collateral arteries for treatment of hepatocellular carcinoma in the caudate lobe of the liver［J］. Cardiovasc Intervent Radiol， 2015， 38： 389- 396.
［16］ Shiozawa S， Tsuchiya A， Endo S， et al. Transradial approach for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma： comparison with conventional transfemoral approach［J］. J Clin Gastroenterol， 2003， 37： 412- 417.
［17］中华医学会放射学分会介入学组协作组．原发性肝细胞癌经导管肝动脉化疗性栓塞治疗技术操作规范专家共识［J］．中华放射学杂志， 2011， 45： 908- 912．
［18］ Tzeng WS， Wu RH， Chang SC， et al. Ionic versus nonionic contrast media solvents used with an epirubicin- based agent for transarterial chemoembolization of hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2008， 19： 342- 350.
［19］ Irie T， Kuramochi M， Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon- occluded transarterial chemoembolization： measurement of balloon- occluded arterial stump pressure［J］. Cardiovasc Intervent Radiol， 2013， 36： 706- 713.
［20］ Imai N， Ishigami M， Ishizu Y， et al. Transarterial chemoembo- lization for hepatocellular carcinoma： a review of techniques［J］. World J Hepatol， 2014， 6： 844- 850.
［21］ Vogl TJ， Nour- Eldin NE， Emad- Eldin S， et al. Portal vein thrombosis and arterioportal shunts： effects on tumor response after chemoembolization of hepatocellular carcinoma［J］. World J Gastroenterol， 2011， 17： 1267- 1275.
［22］ Miyayama S， Matsui O， Yamashiro M， et al. Ultraselective transcatheter arterial chemoembolization with a 2- F tip microcatheter for small hepatocellular carcinomas： relationship between local tumor recurrence and visualization of the portal vein with iodized oil［J］. J Vasc Interv Radiol， 2007， 18： 365 376.
［23］ de Baere T， Arai Y， Lencioni R， et al. Treatment of liver tumors with lipiodol TACE： technical recommendations from experts opinion［J］. Cardiovasc Intervent Radiol， 2016， 39： 334- 343.
［24］ Bruix J， Sherman M， Practice Guidelines Committee， et al. Management of hepatocellular carcinoma［J］. Hepatology， 2005， 42： 1208- 1236.
［25］ Omata M， Lesmana LA， Tateishi R， et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma［J］. Hepatol Int， 2010， 4： 439- 474.
［26］中华医学会放射学分会对比剂安全使用工作组. 碘对比剂使用指南（第2版）［J］. 中华放射学杂志， 2013， 47： 869- 872.
［27］施海彬，顾建平，何旭，等．外周血管假性动脉瘤的介入治疗［J］．中华放射学杂志， 2005， 39： 929- 931．
［28］罗鹏飞，符力，陈晓明，等．肝癌介入治疗后胆汁瘤的形成与临床意义［J］．中华放射学杂志， 2000， 34： 36- 39．
［29］施昌盛，杨庆，施振静，等．肝癌TACE术后并发碘油异位脑栓塞二例［J］．中华介入放射学电子杂志， 2016， 4： 243- 245．
［30］ Kudo M， Matsui O， Izumi N， et al. Transarterial chemoembolization failure/refractoriness： JSH- LCSGJ criteria 2014 update［J］. Oncology， 2014， 87（Suppl 1）： 22- 31.
［31］ Lencioni R， Llovet JR. Assessment for hepatocellular carcinoma［J］. Semin Liver Dis， 2010， 30： 52- 60.
［32］ Llovet JM， Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma： chemoembolization improves survival［J］. Hepatology， 2003， 37： 429- 442.
［33］ Lo CM， Liu CL， Chan SC， et al. A randomized， controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma［J］. Ann Surg， 2007， 245： 831- 842.
［34］ Cabibbo G， Enea M， Attanasio M， et al. A meta- analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma［J］. Hepatology， 2010， 51： 1274- 1283.
［35］ Li SL， Su M， Peng T， et al. Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients［J］. Asian Pac J Cancer Prev， 2013， 14： 217- 223.
［36］ Zhang S， Yue M， Shu R， et al. Recent advances in the management of hepatocellular carcinoma［J］. J BUON， 2016， 21： 307- 311.
［37］ Fu Y， Zhao X， Yun Q， et al. Transarterial chemoembolization （TACE） plus percutaneous ethanol injection（PEI） for the treatment of unresectable hepatocellular carcinoma： a meta- analysis of randomized controlled trials［J］. Int J Clin Exp Med， 2015， 8： 10388- 10400.
［38］ Si ZM， Wang GZ， Qian S， et al. Combination therapies in the management of large（≥5 cm）hepatocellular carcinoma： microwave ablation immediately followed by transarterial chemoembolization［J］. J Vasc Interv Radiol， 2016， 27： 1577- 1583.
［39］ Liang SX， Zhu XD， Xu ZY， et al. Radiation- induced liver disease in three- dimensional conformal radiation therapy for primary liver carcinoma： the risk factors and hepatic radiation tolerance［J］. Int J Radiat Oncol Biol Phys， 2006， 65： 426- 434.
［40］ Lu Z， Wen F， Guo Q， et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma： a meta- analysis of randomized- controlled trials［J］. Eur J Gastroenterol Hepatol， 2013， 25： 187- 194.
［41］ Peng ZW， Guo RP， Zhang YJ， et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］. Cancer， 2012， 118： 4725- 4736.
［42］ Yeh SA， Chen YS， Perng DS. The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］. J Radiat Res， 2015， 56： 325- 331.
［43］ Chern MC， Chuang VP， Liang CT， et al. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion： safety， efficacy， and prognostic factors［J］. J Vasc Interv Radiol， 2014， 25： 32- 40.
［44］ Gao S， Zhang PJ， Guo JH， et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients［J］. World J Gastroenterol， 2015， 21： 10443- 10452.
［45］ Lyu N， Lin Y， Kong Y， et al. FOXAI： a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma［J］. Gut， 2018， 67： 395- 396.
［46］ Lu J， Guo JH， Zhu HD， et al. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma： a single- center experience［J］. J Vasc Interv Radiol， 2017， 28： 786.e3- 794.e3.
［47］ Yang M， Fang Z， Yan Z， et al. Transarterial chemoembolisation （TACE） combined with endovascular implantation of an iodine- 125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone： a two- arm， randomised clinical trial［J］. J Cancer Res Clin Oncol， 2014， 140： 211- 219.
［48］ Kang J， Nie Q， Du R， et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis［J］. Mol Clin Oncol， 2014， 2： 43- 50.
［49］ Zhang XB， Wang JH， Yan ZP， et al. Hepatocellular carcinoma invading the main portal vein： treatment with transcatheter arterial chemoembolization and portal vein stenting［J］. Cardiovasc Intervent Radiol， 2009， 32： 52- 61.
［50］ Zhang XB， Wang JH， Yan ZP， et al. Hepatocellular carcinoma with main portal vein tumor thrombus treatment with 3- dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization［J］. Cancer， 2009， 115： 1245- 1252.
［51］ Luo JJ， Zhang ZH， Liu QX， et al. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus［J］. Hepatol Int， 2016， 10： 185- 195.
［52］ Yang M， Fang Z， Yan Z， et al. Transarterial chemoembolisation （TACE） combined with endovascular implantation of an iodine- 125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone： a two- arm， randomised clinical trial［J］. J Cancer Res Clin Oncol， 2014， 140： 211- 219.
［53］ Luo J， Yan Z， Liu Q， et al. Endovascular placement of iodine- 125 seed Strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein［J］. J Vasc Interv Radiol， 2011， 22： 479- 489.
［54］ Huo YR， Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma a systematic review and meta- analysis［J］. JAMA Oncol， 2015， 1： 756- 765.
［55］ Long J， Zheng JS， Sun B， et al. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization： a prospective study［J］. Hepatol Int， 2016， 10： 175- 184.
［56］ Duan F， Yu W， Wang Y， et al. Trans- arterial chemoembolization and external beam radiation therapy for treatment of hepatocellular carcinoma with a tumor thrombus in the inferior vena cava and right atrium［J］. Cancer Imaging， 2015， 15： 7.
［57］ Yang QH， Zhang W， Liu QX， et al. TACE combined with implantation of irradiation stent versus TACE combine with bare stent for HCC complicated by IVCTT［J］. Cardiovasc Intervent Radiol， 2016， 39： 1280- 1288.
［58］ Bruls S， Joskin J， Chauveau R， et al. Ruptured hepatocellular carcinoma following transcatheter arterial chemoembolization［J］. JBR- BTR， 2011， 94： 68- 70.
［59］ Ren ZG， Lin ZY， Xia JL， et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor： a retrospective control study［J］. World J Gastroenterol， 2004， 10： 2791- 2794.
［60］徐国斌，易广新，熊斌，等．原发性肝癌术后早期肝内复发转移36例的介入治疗［J］．介入放射学杂志， 2013， 22： 325- 328．
［61］ Cheng X， Sun P， Hu QG， et al. Transarterial （chemo）embolization for curative resection of hepatocellular carcinoma： a systematic review and meta- analyses［J］. J Cancer Res Clin Oncol， 2014， 140： 1159- 1170.
［62］冯超，赵剑波，陈勇，等．原发性肝癌切除术后预防性经肝动脉介入治疗：肝动脉化疗栓塞术和化疗灌注术比较［J］．介入放射学杂志， 2014， 23： 679- 682．
［63］ Xu F， Huang YQ， Wu L， et al. Is postoperative adjuvant transcatheter arterial chemoembolization necessary for small hepatocellular carcinoma patients： a randomized controlled trial［J］. Acad J Second Mil Med Univ， 2012， 33： 274- 279.
［64］ Cheng HY， Wang X， Chen D， et al. The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma［J］. World J Gastroenterol， 2005， 11： 3644- 3646.
［65］何程祖． TACE与TAI对原发性肝癌切除术后预防性肝动脉介入治疗疗效的影响分析［J］．肝胆外科杂志， 2016， 24： 370- 374．
［66］ Abdel- Rehim M， Ronot M， Sibert A， et al. Assessment of liver ablation using cone beam computed tomography［J］. World J Gastroenterol， 2015， 21： 517- 524.
［67］ Dietrich CF， Lorentzen T， Appelbaum L， et al. EFSUMB guidelines on interventional ultrasound（INVUS）， part Ⅲ- abdominal treatment procedures（short version）［J］. Ultraschall Med， 2016， 37： 27- 45.
［68］ Chen MS， Li JQ， Zheng Y， et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma［J］. Ann Surg， 2006， 243： 321- 328.
［69］ Morimoto M， Numata K， Kondou M， et al. Midterm outcomes in patients with intermediate- sized hepatocellular carcinoma： a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization［J］. Cancer， 2010， 116： 5452- 5460.
［70］ Zeng ZC， Tang ZY， Fan J， et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma［J］. Cancer J， 2004， 10： 307- 316.
［71］ Meng MB， Cui YL， Lu Y， et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma： a systematic review and meta- analysis［J］. Radiother Oncol， 2009， 92： 184- 194.
［72］ Zeng ZC， Fan J， Tang ZY， et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus［J］. Int J Radiat Oncol Biol Phys， 2005， 61： 432- 443.
［73］ Lau WY， Teoh YL， Win KM， et al. Current role of selective internal radiation with yttrium- 90 in liver tumors［J］. Future Oncol， 2016， 12： 1193- 1204.
［74］ Xu J， Shen ZY， Chen XG， et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation［J］. Hepatology， 2007， 45： 269- 276.
［75］ Raoul JL， Guyader D， Bretagne JF， et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis： intra- arterial iodine- 131- iodized oil versus medical support［J］. J Nucl Med， 1994， 35： 1782- 1787.
［76］刘德鑫，王伟，李新丰，等．肝动脉化疗栓塞联合粒子植入治疗肝癌自发性破裂出血的临床研究［J］．介入放射学杂志， 2015， 24： 999- 1003．
［77］ Lee TY， Lin CC， Chen CY， et al. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early- intermediate stage hepatocellular carcinoma： a post hoc analysis of the START trial［J］. Medicine （Baltimore）， 2017， 96： e7655.
［78］ 2018 ASCO Annual Meeting abstract 4017， Masatoshi Kudo［EB/OL］.https：//meetinglibrary.asco.org/record/160074/abstract.
［79］ Liu C， Xing W， Si T， et al. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus： a retrospective study［J］. Oncotarget， 2017， 8： 100734- 100745.
［80］ Lu W， Jin XL， Yang C， et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma： a single- center randomized controlled trial［J］. Cancer Biol Ther， 2017， 18： 433- 438.
［81］ Kong Y， Sun L， Hou Z， et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma［J］. Oncotarget， 2017， 8： 105596- 105605.
［82］陈德连，江会红．榄香烯联合介入治疗中晚期肝癌患者的近期疗效［J］．广州中医药大学学报， 2016， 33： 27- 30．
［83］陈骏，王峰，杨葆华，等．榄香烯联合介入治疗中晚期肝癌92例［J］．介入放射学杂志， 2002， 11： 210- 212．
［84］储真真，林志杰，陈历宏，等．莲龙消积方联合榄香烯介入治疗中晚期原发性肝癌临床疗效评价［J］．中华中医药杂志， 2016， 31： 2421- 2424．
［85］冯惠岗，梁奇伟，郭惠庄，等．甘草酸二铵联合槐耳颗粒治疗肝癌TACE术后栓塞综合征临床观察［J］．中华介入放射学电子杂志， 2016， 4： 197- 201．
［86］高继良．肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究［J］．中国中药杂志， 2014， 39： 2367- 2369．
［87］ Chen Q， Shu C， Laurence AD， et al. Effect of huaier granule on recurrence after curative resection ofHCC： a multicentre，randomised clinical trial［J］. Gut， 2018， 67： 2006- 2016.
［88］ Huang W， You L， Yang S， et al. Metronomic S- 1 chemotherapy plus transcatheter arterial chemoembolization（TACE）： a promising treatment of hepatocellular carcinoma refractory to TACE［J］. J Buon， 2016， 21： 909- 916.
［89］ Li Z， Zhou JX， Ren JZ， et al. Clinical value of iodine- 131 metuximab infusion combined with TACE for treatment of patients with post- intervention relapse of mid or advanced stage hepatocellular carcinoma［J］. Zhonghua Gan Zang Bing Za Zhi， 2013， 21： 728- 733.
［90］ Pinter M， Ulbrich G， Sieghart W， et al. Hepatocellular carcinoma： a phase Ⅱ randomized controlled double- blind trial of trans- arterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo［J］. Radiology， 2015， 277： 903- 912.
［91］ Wang W， Bai W， Wang E， et al. mRECIST response combined with sorafenib- related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib［J］. Int J Cancer， 2017， 140： 390- 399.
［92］ Sun HC， Tang ZY， Wang L， et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV- related hepatocellular carcinoma： a randomized clinical trial［J］. J Cancer Res Clin Oncol， 2006， 132： 458- 465.
［93］程树群，吴孟超，陈汉，等．胸腺肽α1对原发性肝癌术后复发的影响［J］．中华肝胆外科杂志， 2004， 10： 19- 20．
［94］ Lee JH， Lee JH， Lim YS， et al. Adjuvant immunotherapy with autologous cytokine- induced killer cells for hepatocellular carcinoma［J］. Gastroenterology， 2015， 148： 1383- 1391.

相似文献/References:

[1]姚雪松,李槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃｅｖａｌｕａｔｉｏｎｃｒｉｔｅｒｉｏｎｏｆｉｎｏｐｅｒａｂｌｅｈｅｐａｔｏｃｅｌｌｕｌａｒｃａｒｃｉｎｏｍａｓ：ｍｏｄｉｆｉｅｄＲＥＣＩＳＴａｓａｍｏｒｅｒｅｌｉａｂｌｅｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(12):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅｔｒａｎｓｆｏｒｍａｔｉｏｎｐａｔｔｅｒｎｏｆｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎａｆｔｅｒｔｒａｎｓｃａｔｈｅｔｅｒａｒｔｅｒｉａｌｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎｉｎｐａｔｉｅｎｔｓｗｉｔｈｈｅｐａｔｏｃｅｌｌｕｌａｒｃａｒｃｉｎｏｍａ：ｉｔｓｃｌｉｎｉｃａｌｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(12):333.
[3]孙磊,施海彬,刘圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅｆａｃｔｏｒｓｒｅｌａｔｅｄｔｏｔｈｅｆｏｒｍａｔｉｏｎｏｆａｒｔｅｒｉｏｐｏｒｔａｌｓｈｕｎｔｉｎｇｉｎｐａｔｉｅｎｔｓｗｉｔｈｈｅｐａｔｏｃｅｌｌｕｌａｒｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(12):206.
[4]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(12):621.
[5]沈海洋,刘瑞宝,刘岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(12):469.
[6]李晓峰,钱国军,张磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(12):974.
[7]赵艳,韩国宏,白苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(12):78.
[8]彭辽河,胡晓燕,李杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(12):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(12):520.
[10]姚雪松,闫东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(12):769.
[11]王以浪,王亚非,张亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(12):406.
[12]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(12):1114.
[13]刘璐璐,邵国良,庞佩佩.磁共振弥散加权和动态增强成像评价晚期肝癌TACE术疗效研究进展 [J].介入放射学杂志,2017,(08):756.
　LIU Lulu,SHAO Guoliang,PANG Peipei.Application of diffusion- weighted and dynamic contrast- enhanced MRI in evaluating the curative effect of TACE for advanced hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(12):756.
[14]张申,张磊,仲斌演,等.“TACE抵抗/失败”——需要全面认识[J].介入放射学杂志,2020,29(08):743.
　ZHANG Shen,ZHANG Lei,ZHONG Binyan,et al.Comprehensive understanding of the concept and connotation of “TACE- failure/refractoriness”[J].journal interventional radiology,2020,29(12):743.
[15]刘嵘,程永德,王小林,等.中国肝细胞癌TACE治疗的历史、现状和展望 ——纪念我国介入放射学奠基人林贵教授[J].介入放射学杂志,2022,31(08):743.
　LIU Rong,CHENG Yongde,WANG Xiaolin,et al.The history, status and future of transarterial chemoembolization of hepatocellular carcinoma in China: in memory of Professor Gui Lin, the founder of interventional radiology in China[J].journal interventional radiology,2022,31(12):743.
[16]夏子聪,赵辉.改善经导管动脉化疗栓塞术疗效的临床及基础研究进展[J].介入放射学杂志,2023,32(07):705.
　XIA Zicong,ZHAO Hui..Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization[J].journal interventional radiology,2023,32(12):705.
[17]陆一峰,王祁,何忠明.构建基于控制营养状况评分的列线图预测肝细胞癌TACE治疗患者预后[J].介入放射学杂志,2023,32(12):1190.
　LU Yifeng,WANG Qi,HE Zhongming..Construction of a nomogram based on controlling nutritional status score for predicting the prognosis of hepatocellular carcinoma patients after receiving TACE[J].journal interventional radiology,2023,32(12):1190.
[18]管清龙,陈海波,刘成龙,等.体素内不相干运动-弥散加权成像评价不同栓塞材料经动脉化疗栓塞治疗肝细胞癌效果及预后[J].介入放射学杂志,2024,33(02):140.
　GUAN Qinglong,CHNE Haibo,LIU Chenglong,et al.The application of IVIM-DWI in evaluating the efficacy and prognosis of TACE using different embolization materials for hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):140.
[19]隰子涵,杨永波,邵国良.MRI和临床危险因素对中晚期肝细胞癌首次D-TACE近期疗效预测价值分析[J].介入放射学杂志,2024,33(04):376.
　XI Zihan,YANG Yongbo,SHAO Guoliang..The value of MRI and clinical risk factors in predicting the short-term efficacy of initial D-TACE in patients with intermediate and advanced stage hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):376.

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

文章信息/Info

参考文献/References:

相似文献/References:

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics